Instrument Inactif

Autres langues Ibere Pharmaceuticals

Actions

Ibere Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22
Ibere Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/08/22
Ibere Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22
Ibere Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2021	31/03/22
Ibere Pharmaceuticals Auditor Raises 'Going Concern' Doubt	31/03/22
Ibere Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	12/11/21
Certain Class B Ordinary Shares of Ibere Pharmaceuticals are subject to a Lock-Up Agreement Ending on 24-AUG-2021.	24/08/21
Ibere Pharmaceuticals Reports Earnings Results for the Second Quarter Ended June 30, 2021	16/08/21
Ibere Pharmaceuticals : Letter dated August 4, 2021 from Marcum LLP (Form 8-K)	04/08/21
Ibere Pharmaceuticals : Receives Expected NYSE Notice Regarding Delayed Quarterly Report	29/05/21
Ibere Pharmaceuticals : Receives Expected NYSE Notice Regarding Delayed Quarterly Report (Form 8-K)	28/05/21
Ibere Pharmaceuticals announced that it has received $4.835 million in funding	02/03/21
Ibere Pharmaceuticals has completed an IPO in the amount of $120 million.	26/02/21
Ibere Pharmaceuticals announced that it expects to receive $4.835 million in funding	25/02/21
Ibere Pharmaceuticals has filed an IPO in the amount of $100 million.	08/02/21

Aucun résultat pour cette recherche